Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
Sep 12, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 …
Long-acting injectable lenacapavir continues to show promising …
Sep 26, 2024 · WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
Twice-yearly shot proves successful at preventing HIV infection …
Jul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
New HIV drug can only offer hope of ending AIDS if all have …
GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Long-acting injectable lenacapavir proves effective in HIV …
Jul 26, 2024 · WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women. This represents a significant breakthrough in HIV prevention.
Full Efficacy and Safety Results for Gilead Investigational Twice ...
Jul 24, 2024 · Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at birth).
Gilead and Merck Announce Phase 2 Data Showing a ... - Business …
1 day ago · Lenacapavir is being evaluated as a potential long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program.
Gileads Twice Yearly Lenacapavir Demonstrated 100 Efficacy and ...
Jun 20, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with p<0.0001 for both endpoints.
Gilead Shot Provides Total Protection From HIV in Trial of Young ...
Jun 21, 2024 · It tested whether the every-six-months injection of lenacapavir, made by Gilead Sciences, would provide better protection against H.I.V. infection than two other drugs in wide use in high-income...
NIH Statement on Preliminary Efficacy Results of Twice-Yearly ...
Jun 26, 2024 · The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor.